Merck To Await Additional Torcetrapib Data Before Advancing CETP Agent
Executive Summary
Merck will await further data regarding Pfizer's terminated HDL/LDL compound torcetrapib/Lipitor before moving forward with its own cholesteryl ester transfer protein inhibitor
You may also be interested in...
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug
Other CETP Inhibitors Could Escape Torcetrapib Trap, ACC Studies Suggest
The failure of Pfizer's torcetrapib need not be the death knell of the cholesteryl ester transfer protein inhibitor class, according to analysis of imaging studies presented at the American College of Cardiology Scientific Sessions, because there are several plausible reasons that the lack of efficacy could be due to molecule-specific problems